TY - JOUR
T1 - Modulation of polycystic kidney disease severity by phosphodiesterase 1 and 3 subfamilies
AU - Ye, Hong
AU - Wang, Xiaofang
AU - Sussman, Caroline R.
AU - Hopp, Katharina
AU - Irazabal, Maria V.
AU - Bakeberg, Jason L.
AU - LaRiviere, Wells B.
AU - Manganiello, Vincent C.
AU - Vorhees, Charles V.
AU - Zhao, Haiqing
AU - Harris, Peter C.
AU - Van Deursen, Jan
AU - Ward, Christopher J.
AU - Torres, Vicente E.
N1 - Publisher Copyright:
Copyright © 2016 by the American Society of Nephrology.
PY - 2016/5
Y1 - 2016/5
N2 - Aberrant intracellular calciumlevels and increased cAMP signaling contribute to the development of polycystic kidney disease (PKD). cAMP can be hydrolyzed by various phosphodiesterases (PDEs). To examine the role of cAMP hydrolysis and the most relevant PDEs in the pathogenesis of PKD, we examined cyst development in Pde1- or Pde3-knockout mice on the Pkd22/WS25 background (WS25 is an unstable Pkd2 allele). These PDEs were selected because of their importance in cross-talk between calcium and cyclic nucleotide signaling (PDE1), control of cell proliferation and cystic fibrosis transmembrane conductance regulator (CFTR) -driven fluid secretion (PDE3), and response to vasopressin V2 receptor activation (both). In Pkd22/WS25 mice, knockout of Pde1a, Pde1c, or Pde3a but not of Pde1b or Pde3b aggravated the development of PKD and was associated with higher levels of protein kinase A- phosphorylated (Ser133) cAMP-responsive binding protein (P-CREB), activating transcription factor-1, and CREB-induced CRE modulator proteins in kidney nuclear preparations. Immunostaining also revealed higher expression of P-CREB in Pkd22/WS25;Pde1a2/2, Pkd22/WS25;Pde1c2/2, and Pkd22/WS25;Pde3a2/2 kidneys. The cystogenic effect of desmopressin administration was markedly enhanced in Pkd22/WS25;Pde3a2/2 mice, despite PDE3 accounting for only a small fraction of renal cAMP PDE activity. These observations show that calcium- and calmodulindependent PDEs (PDE1A and PDE1C) and PDE3A modulate the development of PKD, possibly through the regulation of compartmentalized cAMP pools that control cell proliferation and CFTR-driven fluid secretion. Treatments capable of increasing the expression or activity of these PDEs may, therefore, retard the development of PKD.
AB - Aberrant intracellular calciumlevels and increased cAMP signaling contribute to the development of polycystic kidney disease (PKD). cAMP can be hydrolyzed by various phosphodiesterases (PDEs). To examine the role of cAMP hydrolysis and the most relevant PDEs in the pathogenesis of PKD, we examined cyst development in Pde1- or Pde3-knockout mice on the Pkd22/WS25 background (WS25 is an unstable Pkd2 allele). These PDEs were selected because of their importance in cross-talk between calcium and cyclic nucleotide signaling (PDE1), control of cell proliferation and cystic fibrosis transmembrane conductance regulator (CFTR) -driven fluid secretion (PDE3), and response to vasopressin V2 receptor activation (both). In Pkd22/WS25 mice, knockout of Pde1a, Pde1c, or Pde3a but not of Pde1b or Pde3b aggravated the development of PKD and was associated with higher levels of protein kinase A- phosphorylated (Ser133) cAMP-responsive binding protein (P-CREB), activating transcription factor-1, and CREB-induced CRE modulator proteins in kidney nuclear preparations. Immunostaining also revealed higher expression of P-CREB in Pkd22/WS25;Pde1a2/2, Pkd22/WS25;Pde1c2/2, and Pkd22/WS25;Pde3a2/2 kidneys. The cystogenic effect of desmopressin administration was markedly enhanced in Pkd22/WS25;Pde3a2/2 mice, despite PDE3 accounting for only a small fraction of renal cAMP PDE activity. These observations show that calcium- and calmodulindependent PDEs (PDE1A and PDE1C) and PDE3A modulate the development of PKD, possibly through the regulation of compartmentalized cAMP pools that control cell proliferation and CFTR-driven fluid secretion. Treatments capable of increasing the expression or activity of these PDEs may, therefore, retard the development of PKD.
UR - http://www.scopus.com/inward/record.url?scp=85019200788&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019200788&partnerID=8YFLogxK
U2 - 10.1681/ASN.2015010057
DO - 10.1681/ASN.2015010057
M3 - Article
C2 - 26374610
AN - SCOPUS:85019200788
SN - 1046-6673
VL - 27
SP - 1312
EP - 1320
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 5
ER -